aEnlist the different types of receptors with examples of drugs acting

(a)Enlist the different types of receptors with examples of drugs acting through them. (b) Describe the factors modifying drug action and their clinical significance

Reading File

Finding Sources

Searching PubMed

drug response AND pharmacogenomics

Searching the Web

drug receptor types ligand gated ion channels G protein coupled receptors enzyme linked intracellular receptors pharmacology

Finding Sources

Reading File

Reading Web Page

https://www.ncbi.nlm.nih.gov/books/NBK554403

(a) Types of receptors with examples of drugs acting through them

A receptor is a macromolecule, usually a protein, with which a drug interacts to produce its pharmacological effect. The four major receptor families are:

Receptor type	Mechanism and time course	Examples of receptors	Drugs acting through them
1. Ligand-gated ion channel receptors	Binding directly opens or closes an ion channel. Effects occur in milliseconds.	Nicotinic ACh, GABA-A, NMDA, 5-HT3 receptors	Nicotine activates nicotinic receptors; suxamethonium activates nicotinic receptors at NMJ; benzodiazepines positively modulate GABA-A receptors; ondansetron blocks 5-HT3 receptors.
2. G-protein-coupled receptors (GPCRs)	Seven-transmembrane receptors coupled to G proteins. They alter second messengers such as cAMP, IP3, DAG, Ca²⁺ and ion channels. Effects occur in seconds to minutes.	Adrenergic, muscarinic, dopamine, histamine, opioid, angiotensin receptors	Salbutamol activates β2 receptors; propranolol blocks β receptors; atropine blocks muscarinic receptors; morphine activates μ-opioid receptors; losartan blocks AT1 receptors.
3. Enzyme-linked or catalytic receptors	Receptor either has intrinsic enzyme activity or is coupled to an intracellular enzyme. Usually causes phosphorylation and altered cell function. Effects occur in minutes to hours.	Insulin receptor and growth-factor receptors: receptor tyrosine kinases; cytokine receptors coupled to JAK-STAT; natriuretic peptide receptors with guanylyl cyclase activity	Insulin activates insulin receptor tyrosine kinase; erythropoietin activates a cytokine receptor linked to JAK-STAT; filgrastim acts through G-CSF receptor; nesiritide acts through natriuretic peptide receptors.
4. Intracellular or nuclear receptors	Lipid-soluble drug enters cell, binds cytoplasmic or nuclear receptor, and changes gene transcription. Effects begin slowly, over hours to days, but may persist long.	Glucocorticoid, mineralocorticoid, estrogen, progesterone, androgen, thyroid hormone, vitamin D receptors	Prednisolone/dexamethasone act at glucocorticoid receptors; ethinyl estradiol at estrogen receptors; levothyroxine at thyroid hormone receptors; calcitriol at vitamin D receptors.

Additional membrane receptor systems

These are often included under enzyme-linked or other cell-surface receptors:

Receptor guanylyl cyclase: activated by atrial and brain natriuretic peptides, increasing cGMP.
Cytokine receptors: lack intrinsic kinase activity but activate JAK-STAT pathways. Examples include receptors for erythropoietin, growth hormone and interferons.
Receptor serine/threonine kinase: e.g., TGF-β receptor.
Toll-like and TNF receptors: important in immune and inflammatory signaling.

Cellular receptor classes relevant to therapy include GPCRs, ligand-gated ion channels, enzyme-linked receptors, other surface receptors and nuclear receptors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics, p. 76.

(b) Factors modifying drug action and their clinical significance

Drug response varies between patients and may also vary in the same patient at different times. This results from pharmacokinetic factors, pharmacodynamic factors, patient characteristics, disease and environmental influences.

1. Dose

A larger dose generally produces a greater response until the maximum effect is reached.

Clinical significance

Too small a dose causes therapeutic failure.
Excess dose can cause toxicity.
Drugs with a narrow therapeutic index, such as digoxin, lithium, warfarin and aminoglycosides, require careful dose selection and often therapeutic drug monitoring.

2. Route of administration

The route determines the onset, intensity and duration of action.

Examples

Sublingual nitroglycerin has rapid action because it bypasses first-pass metabolism.
Oral drugs may have slow or variable absorption.
Intravenous drugs have immediate effect and a greater risk of acute toxicity.
Inhaled salbutamol provides local airway action with fewer systemic effects.

Clinical significance: The route is selected according to urgency, desired site of action, patient condition and drug properties.

3. Dosage form and formulation

The same drug may differ in onset and duration depending on formulation.

Examples

Immediate-release versus sustained-release nifedipine.
Enteric-coated aspirin reduces direct gastric irritation.
Depot antipsychotic preparations improve adherence.

Clinical significance: Altering a formulation without adjusting dose or frequency can result in treatment failure or toxicity.

4. Age

Children

Drug-metabolizing enzymes, renal function, body-water content and receptor responses change during development.

Clinical significance

Doses are usually calculated by body weight or body surface area.
Chloramphenicol may cause gray baby syndrome because neonatal glucuronidation is immature.
Sulfonamides can displace bilirubin and predispose neonates to kernicterus.

Elderly

Renal and hepatic clearance often decline; body fat increases; multiple diseases and polypharmacy are common.

Clinical significance

Use “start low and go slow.”
Long-acting benzodiazepines may cause excessive sedation, falls and hip fractures.
Dose reduction is often needed for renally eliminated drugs such as digoxin, aminoglycosides and some direct oral anticoagulants.

In children, developmental changes in body compartments and organ function modify drug response; in older adults, altered pharmacokinetics, pharmacodynamics, comorbidity and polypharmacy increase adverse drug reactions. Harrison’s Principles of Internal Medicine, p. 254.

5. Body weight and body composition

Drug distribution is affected by total body water, fat content and lean body mass.

Clinical significance

Many pediatric doses are prescribed in mg/kg.
Obesity may increase the volume of distribution of lipid-soluble drugs, such as diazepam.
Reduced body mass in frail older patients can increase effective drug concentration.

6. Sex and pregnancy

Sex hormones, body composition, enzyme activity and pregnancy-related physiological changes may alter responses.

Clinical significance

Pregnancy increases plasma volume, cardiac output and renal blood flow, potentially lowering concentrations of some drugs.
Teratogenicity must be considered: e.g., isotretinoin, ACE inhibitors and valproate should be avoided in pregnancy where appropriate.
Warfarin crosses the placenta and is contraindicated in pregnancy, whereas heparin is preferred when anticoagulation is required.

7. Genetic factors and pharmacogenetics

Genetic variations may alter drug-metabolizing enzymes, transporters, receptors or immune responses.

Genetic variation	Drug affected	Clinical outcome
G6PD deficiency	Primaquine, dapsone, sulfonamides	Hemolytic anemia
Atypical plasma cholinesterase	Succinylcholine	Prolonged apnea
Slow acetylator phenotype, NAT2	Isoniazid	Peripheral neuropathy and toxicity
CYP2C19 poor metabolism	Clopidogrel	Reduced antiplatelet effect
CYP2D6 variation	Codeine	Ineffectiveness in poor metabolizers or opioid toxicity in ultrarapid metabolizers
HLA-B*57:01	Abacavir	Severe hypersensitivity reaction
HLA-B*15:02	Carbamazepine	Stevens-Johnson syndrome/toxic epidermal necrolysis risk in susceptible populations

Clinical significance: Pharmacogenetic testing can help select a drug, avoid severe adverse reactions or individualize dosage.

Drug-response variability reflects drug factors, environmental factors, clinical factors such as age and organ function, and genetic factors. Pharmacogenes can affect either drug concentration or drug effect. Goodman & Gilman’s The Pharmacological Basis of Therapeutics, pp. 80-81.

8. Pathological states

Liver disease

Reduces metabolism of many drugs and reduces albumin synthesis.

Examples and significance

Diazepam, warfarin and propranolol may have prolonged effects.
Lower doses may be necessary in cirrhosis.

Renal impairment

Decreases excretion of renally cleared drugs and active metabolites.

Examples and significance

Dose adjustment is needed for aminoglycosides, digoxin, metformin and many antimicrobials.
Failure to adjust may cause nephrotoxicity, ototoxicity, arrhythmia or lactic acidosis.

Cardiac failure or shock

Reduced tissue perfusion may reduce hepatic and renal clearance.

Clinical significance: Drugs with high hepatic extraction, such as lidocaine, may accumulate.

Endocrine disorders

Hyperthyroidism increases sensitivity to catecholamines.
Hypothyroidism can increase sensitivity to CNS depressants and decrease drug metabolism.
Diabetes affects insulin requirements and response to hypoglycemic drugs.

Hypoalbuminemia and malnutrition

Increase the unbound fraction of highly protein-bound drugs.

Example: Increased free warfarin or phenytoin can increase toxicity.

9. Drug interactions

A second drug can increase or decrease the effect of the first drug.

Pharmacokinetic interactions

Alter absorption, distribution, metabolism or excretion.

Rifampicin induces CYP enzymes and can reduce efficacy of oral contraceptives and warfarin.
Macrolides, azole antifungals and some antivirals inhibit CYP3A4 and may increase toxicity of statins or other substrates.
Antacids can reduce absorption of tetracyclines and fluoroquinolones.
NSAIDs can reduce renal elimination of lithium, causing toxicity.

Pharmacodynamic interactions

Effects occur at the receptor, organ or physiological-system level.

Nitrates plus sildenafil can cause profound hypotension.
Opioids plus benzodiazepines can cause severe respiratory depression.
Warfarin plus aspirin increases bleeding risk.

Clinical significance: Obtain a complete medication history, including OTC products, herbal products, supplements and eye drops. Drug interactions may change drug disposition or alter response without changing drug concentration. Harrison’s Principles of Internal Medicine, p. 255.

10. Diet, food, alcohol, smoking and environment

Factor	Example	Clinical significance
Food	Tetracycline with milk	Calcium chelation reduces absorption.
Vitamin K-rich food	Warfarin	May reduce anticoagulant effect.
Grapefruit juice	Simvastatin, some calcium-channel blockers	CYP3A4 inhibition may raise drug level and toxicity.
Alcohol	Metronidazole	Disulfiram-like reaction.
Smoking	Theophylline, clozapine	Induces CYP1A2, reducing drug levels. Stopping smoking may increase toxicity unless dose is revised.
Exercise, heat, dehydration	Insulin, diuretics, lithium	May increase hypoglycemia, dehydration or lithium toxicity.

11. Tolerance, tachyphylaxis and dependence

Tolerance: Gradual reduction in response after repeated administration, requiring a larger dose for the same effect.
- Examples: opioids, benzodiazepines, nitrates, β2 agonists.
Tachyphylaxis: Rapidly developing reduction in response after closely repeated doses.
- Examples: ephedrine, tyramine, nasal decongestants; tolerance to continuous nitrate therapy.
Dependence: Physical or psychological need for a drug, with withdrawal symptoms on stopping it.

Clinical significance

Avoid unnecessary dose escalation.
Use intermittent nitrate-free periods to reduce nitrate tolerance.
Avoid abrupt withdrawal of drugs causing dependence, such as benzodiazepines, opioids, clonidine and corticosteroids.

Continued administration may reduce responsiveness, producing tolerance; rapid reduction in responsiveness is termed tachyphylaxis. Katzung’s Basic and Clinical Pharmacology, p. 66.

12. Receptor number, sensitivity and endogenous mediator concentration

Changes in receptor density, receptor coupling or endogenous agonist concentration alter drug effects.

Examples

Propranolol causes a greater fall in heart rate when catecholamine levels are high, but little effect in a well-trained athlete with low resting sympathetic activity.
Chronic β-agonist exposure can cause β-receptor downregulation and reduced bronchodilator response.
Long-term β-blocker use may cause receptor upregulation; abrupt withdrawal can cause rebound tachycardia or angina.

Clinical significance: Dose should be individualized and some drugs must be tapered rather than abruptly stopped.

13. Idiosyncrasy, allergy and immunological reactions

Idiosyncratic reaction: Unusual, unpredictable response, often genetically determined.
- Example: hemolysis with primaquine in G6PD deficiency.
Drug allergy: Immunologically mediated reaction, not necessarily dose-related.
- Example: anaphylaxis with penicillin.
Pseudoallergic reaction: Mimics allergy without a specific immune mechanism.
- Example: histamine release with some opioids or radiocontrast reactions.

Clinical significance: Stop the suspected drug, treat the reaction promptly, record the allergy clearly, and avoid rechallenge in serious reactions.

14. Psychological factors and adherence

Expectation, anxiety, placebo effect and adherence can alter apparent treatment response.

Clinical significance

Poor adherence may look like drug resistance or treatment failure.
Confirm how the patient takes the medicine before escalating treatment.
Simplified regimens, counseling and long-acting formulations may improve adherence.

Summary

The important factors modifying drug action are:

Dose, route and dosage form
Age, body weight, sex and pregnancy
Genetic constitution
Disease, especially hepatic, renal, cardiac and endocrine disease
Drug-drug, drug-food and environmental interactions
Tolerance, tachyphylaxis and receptor changes
Idiosyncrasy, allergy and psychological factors
Patient adherence

Clinical importance: These factors explain why the same dose can be effective in one patient, ineffective in another, and toxic in a third. Rational prescribing requires individualized drug and dose selection, assessment of organ function, interaction screening, monitoring for response and adverse effects, and patient counseling.

A recent systematic review also supports the relevance of pharmacogenomic variants in preventing drug-related adverse effects, though testing is currently most useful for selected high-risk drug-gene pairs (PMID: 39187310).

This is a shared conversation. Sign in to Orris to start your own chat.